Autologous adipose-derived stromal vascular fraction in patients with systemic sclerosis: 12-month follow-up

Rheumatology (United Kingdom)

Volumn 55, Issue 2, 2015, Pages 301-306

  Guillaume Jugnot, Perrine ^a   Daumas, Aurélie ^a   Magalon, Jérémy ^b   Jouve, Elisabeth ^c   Nguyen, Pierre Sébastien ^d   Truillet, Romain ^c   Mallet, Stéphanie ^e   Casanova, Dominique ^d   Giraudo, Laurent ^b   Veran, Julie ^b   Dignat George, Françoise ^b,c   Sabatier, Florence ^b,c   Magalon, Guy ^c,d   Granel, Brigitte ^a,b  

^a Internal Medicine Department   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c North Hospital   (France)

^d Plastic Surgery Department   (France)

^e Department of Dermatology ^*  (France)

Author keywords

Adipose tissue; Cell therapy; Hand; Stromal vascular fraction; Systemic sclerosis

Indexed keywords

ADIPOSE TISSUE; ADULT; ARTICLE; AUTOLOGOUS ADIPOSE DERIVED STROMAL VASCULAR FRACTION; CELL THERAPY; CLINICAL ARTICLE; COCHIN HAND FUNCTION SCALE; FEMALE; FOLLOW UP; HAND MOVEMENT; HUMAN; MIDDLE AGED; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SCLERODERMA; SCLERODERMA HEALTH ASSESSMENT QUESTIONNAIRE; SKIN FIBROSIS; STROMA CELL; SYSTEMIC SCLEROSIS;

EID: 84961907975     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev323     Document Type: Article

References (8)

1. Guillevin L, Hunsche E, Denton CP et al. Functional impairment of systemic scleroderma patients with digital ulcerations:results from the DUO Registry. Clin Exp Rheumatol 2013;31:71-80.
2. Rannou F, Poiraudeau S, Berezné A et al. Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form Health Survey. Arthritis Rheum 2007;57:94-102.
3. Khanna D, Clements PJ, Furst DE et al. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, doubleblind, placebo-controlled trial. Arthritis Rheum 2009;60:1102-11.
4. Granel B, Daumas A, Jouve E et al. Safety, tolerability and potential efficacy of injection of autologous adiposederived stromal vascular fraction in the fingers of patients with systemic sclerosis: an open-label phase I trial. Ann Rheum Dis 2014; Advance Access published 11 August, doi: 10.1136/annrheumdis-2014-205681.
5. Van den Hoogen F, Khanna D, Fransen J et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2013;65:2737-47.
6. Kowal-Bielecka O, Landewé R, Avouac J et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68:620-8.
7. Bourin P, Bunnell BA, Casteilla L et al. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy 2013;15:641-8.
8. Merkel PA, Herlyn K, Martin RW et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002;46:2410-20.